Ignite Creation Date:
2024-05-06 @ 1:49 AM
Last Modification Date:
2024-10-26 @ 11:10 AM
Study NCT ID:
NCT01905592
Status:
TERMINATED
Last Update Posted:
2022-11-15
First Post:
2013-07-18
Brief Title:
A Phase III Trial of Niraparib Versus Physicians Choice in HER2 Negative Germline BRCA Mutation-positive Breast Cancer Patients
Sponsor:
Tesaro Inc
Organization:
Tesaro Inc
Organization Data
Organization:
Tesaro Inc
Class:
INDUSTRY
Study ID:
213551
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Tesaro Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | NETWORK |
| Breast International Group | OTHER |
| Myriad Genetic Laboratories Inc | INDUSTRY |
| US Oncology Research | INDUSTRY |
| Sarah Cannon | INDUSTRY |
| Facing Our Risk of Cancer Empowered | OTHER |